Paris-based GenSight would likely have been met with open arms on Nasdaq if it had filed for an IPO when biotech offerings and gene therapies were a hot commodity. Instead, it couldn’t fly in New York. But it has found a welcome reception closer to home on the (much smaller) Paris exchange. The biotech, run by serial entrepreneur Bernard Gilly, raised $44 million, according to a report from Reuters, pricing shares at 8 euros. Its syndicate included Novartis, Abingworth, Versant and Medixci. A year ago, GenSight was in the market for a $100 million IPO in the U.S. But times have changed.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,900+ biopharma pros who read Endpoints News by email every day.Free Subscription